Your browser doesn't support javascript.
loading
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim, Emerson A; Bendell, Johanna C; Falchook, Gerald S; Bauer, Todd M; Drake, Charles G; Choe, Jennifer H; George, Daniel J; Karlix, Janet L; Ulahannan, Susanna; Sachsenmeier, Kris F; Russell, Deanna L; Moorthy, Ganesh; Sidders, Ben S; Pilling, Elizabeth A; Chen, Huifang; Hattersley, Maureen M; Das, Mayukh; Kumar, Rakesh; Pouliot, Gayle P; Patel, Manish R.
Afiliación
  • Lim EA; Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York.
  • Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, Colorado.
  • Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Drake CG; Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York.
  • Choe JH; Duke Cancer Institute, Durham, North Carolina.
  • George DJ; Duke Cancer Institute, Durham, North Carolina.
  • Karlix JL; Sarah Cannon Research Institute, Gainesville, Florida.
  • Ulahannan S; Sarah Cannon Research Institute/Oklahoma University, Oklahoma City, Oklahoma.
  • Sachsenmeier KF; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Russell DL; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Moorthy G; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts.
  • Sidders BS; Oncology Biometrics R&D, AstraZeneca, Cambridge, England, United Kingdom.
  • Pilling EA; Oncology Biometrics R&D, AstraZeneca, Cambridge, England, United Kingdom.
  • Chen H; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Hattersley MM; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Das M; Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
  • Kumar R; Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
  • Pouliot GP; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Patel MR; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
Clin Cancer Res ; 28(22): 4871-4884, 2022 11 14.
Article en En | MEDLINE | ID: mdl-36044531
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias de la Próstata Resistentes a la Castración / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Etiology_studies Límite: Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias de la Próstata Resistentes a la Castración / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Etiology_studies Límite: Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos